Amerise BioScie (531681)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a 25% discount to book value: P/B of 0.75 with book value at ₹0.93.
• Piotroski F-Score of 6/9 suggests some balance-sheet and profitability signals are not uniformly weak.
• Tiny ₹5 Cr market cap offers optionality if assets are monetized or operations revive.
• Reported profit growth of 150% shows some earnings improvement from a low base.
• Price is within the 52-week range, suggesting limited speculative froth at the moment.

Concerns

• Earning power is almost nil: ROE is just 1.25% and ROCE is 0.19%, so book value is not being deployed productively.
• Sales growth is 0.00% and the latest quarter shows zero revenue and zero profit, raising going-concern questions.
• P/E of 66 with no dividend is expensive for a business with stagnant sales and minuscule returns.
• Promoter holding and debt/equity are N/A, making governance and leverage impossible to assess.

AI Analysis

Let me look at Amerise BioScie with Graham's discipline. At ₹0.70, the stock trades below book value of ₹0.93 — a P/B of 0.75. That caught my eye. But a cheap price is only a starting point. The company earns a miserable return: ROE is 1.25% and ROCE is 0.19%. Every hundred rupees of equity produces just over a rupee of profit. As a business, it is not earning its keep; with no dividend, I get no return while waiting. Sales growth is exactly 0.00%, and the latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr. The 150% profit growth and PEG of 0.44 look enticing only if you ignore that the base is tiny and the top line is flat. At P/E of 66, I am paying 66 times a fragile profit stream. The Piotroski F-score of 6/9 is modestly encouraging, but with promoter holding N/A and debt/equity N/A, there is not enough transparency to satisfy Mr. Graham. Market cap is just ₹5 Cr — a microcap with liquidity risk. A below-book price gives some asset support, but book value must eventually be converted into earnings, dividends, or cash from a liquidation. Right now, neither the operating engine nor the capital allocation justifies a purchase. I might watch this as an asset play, but the margin of safety is solely in the balance sheet, not in earning power. I would demand years of clean financials, proof that the zero-quarter is an anomaly, and evidence of returning capital before I act.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer